- Author: Manoj Ramachandran, MBBS, MRCS, FRCS; Chief Editor: Harris Gellman, MD more...
The earliest known case of osteogenesis imperfecta (OI) is in a partially mummified infant’s skeleton from ancient Egypt now housed in the British Museum in London. In 1835, Lobstein coined the term osteogenesis imperfecta and was one of the first to correctly understand the etiology of the condition. Other names for OI are Lobstein disease, brittle-bone disease, blue-sclera syndrome, and fragile-bone disease.
OI is one of the most common skeletal dysplasias. It is a generalized disease of connective tissue that may manifest itself with one or more of the following findings:
Additional features, such as constipation and sweating, may also occur. A multidisciplinary approach is required to manage the disease.[1, 2]
In OI, pathologic changes are seen in all tissues of which type 1 collagen is an important constituent (eg, bone, ligament, dentin, and sclera). The basic defect is one of a qualitative or quantitative reduction in type 1 collagen. Mutations in genes encoding type 1 collagen affect the coding of one of the two genes, accounting for approximately 80% of OI cases.[3, 4, 5, 6]
Most cases of OI, previously thought to be either autosomal dominant or autosomal recessive, are now known to arise from autosomal dominant mutations. These mutations are either genetically inherited or new. The inherited mutations have a recurrence risk in subsequent pregnancies of 50% if a parent is affected, whereas the new mutations have an unpredictable recurrence risk.
A small number of cases previously thought to be autosomal recessive have now been proved by molecular and linkage analysis to be secondary to gonadal mosaicism. The recurrence risk for these cases is also unpredictable.
In bone, the degree of histologic change correlates well with the clinical severity of the disease. The disease affects both endochondral and intramembranous ossification.
In OI due to quantitative defects of type 1 collagen, a mild form of the disease occurs. On light microscopy, osteoporotic bone is present, with thick osteoid seams and reduced intercellular matrix. The numbers of osteoclasts and osteocytes are normal. Bone trabeculae are thin and disorganized. Lamellar bone is seen in the diaphysis and metaphysis. On electron microscopy, osteoblasts show distended rough endoplasmic reticulum (possibly because of accumulation of incomplete procollagen molecules), and collagen fibers are of reduced diameter.
In OI due to qualitative defects of type 1 collagen, a severe form of the disease occurs. Light microscopy reveals hyperosteocytosis and increased vascular channels. Other findings are reduced cortical bone thickness, lack of normal cortical bone formation, and disorganization of the growth plate. Woven bone is seen, with minimal osteoid bone and no lamellar bone. Electron microscopy shows poorly preserved osteoblasts and collagen bundles of variable diameter, particularly in the more lethal forms of OI.
The epiphysis and physis tend to be broad and irregular, with disorganization of the proliferative and hypertrophic zones and loss of the typical columnar arrangement. Thinning of the zone of calcified cartilage is evident, along with deficiency of the primary spongiosa of the metaphysis and delay of the secondary centers of ossification in the epiphysis.
With respect to the axial skeleton, scoliosis and kyphosis are common. Vertebral bodies tend to be wedged, translucent, and shallow. Thinning of the skull and multiple ossification centers (wormian bones) are present, particularly in the occiput.
Type 1 collagen is a triple helix formed by two copies of the alpha1 chain and 1 copy of the alpha2 chain. The COL1A gene on chromosome 17 encodes the pro-alpha1 chain, and the COL2A gene on chromosome 2 encodes the pro-alpha2 chain.
The gene sequence coding for the triple-helix domain has a repeating motif of (Gly-X-Y)(n), where X is commonly hydroxyproline and Y is commonly hydroxylysine. Glycine, being the smallest of all amino acids, fits into the core of the superhelix when the chains wind around each other; therefore, glycine plays an important role in the superhelix formation.
In 85-90% of cases, the gene mutation occurs in the region where the exon and intron splice sites are sequenced. All current mutations for type 1 collagen and their associated phenotypes can be found in the Human Type 1 Collagen Mutation Database.
In OI due to quantitative defects of type 1 collagen, mutations are usually found on the COL1A gene. The mutations result in the production of a premature stop codon or a microsense frame shift, which leads to mutant messenger RNA (mRNA) in the nucleus. However, the cytoplasm contains normal alpha1 mRNA; therefore, reduced amounts of structurally normal collagen are produced.
In OI due to qualitative defects of type 1 collagen, autosomal dominant mutations are found on either the COL1A or the COL1B gene. The mutations result in the production of a mixture of normal and mutant collagen chains. Substitution of a larger amino acid (eg, cysteine or alanine) for glycine results in abnormal helix formation, but these chains can combine with normal chains to produce type 1 collagen. The type 1 collagen thus formed is functionally impaired because of the mutant chain; this is the so-called dominant negative mechanism.
Wallace et al, in a report on three patients who had type I OI and primary open angle glaucoma (POAG), identified two novel mutations in COL1A1 in these individuals. They suggested that some mutations in COL1A1 may be causative for OI and POAG. Alternatively, susceptibility genes may interact with mutations in COL1A1 to cause POAG.
The overall incidence of OI is approximately 1 case for every 20,000 live births; however, the mild form is underdiagnosed, and the actual prevalence may be higher. Prevalence appears to be similar worldwide, though an increased rate has been observed in two major tribal groups in Zimbabwe.
OI can present at any age, though the age when symptoms (ie, fractures) begin varies widely. Patients with mild forms may not have fractures until adulthood, or they may present with fractures in infancy. Patients with severe cases present with fractures in utero.
OI is equally common in males and females. It has been described in every human population in which skeletal dysplasias have been studied. The disease appears to have no predilection for a particular race.
Morbidity and mortality associated with OI vary widely, depending on the genotype. (See also the adapted Sillence classification in Presentation.) In addition, variability occurs between individuals with different mutations, and variability has also been observed between unrelated individuals with the same mutations, between members of the same family, and even between identical twins on occasion.
At one extreme, early stillbirths occur, and virtually every bone in the body has multiple fractures. The severe perinatal form (type II) is usually fatal within hours after birth, though some babies survive for several months. At the other extreme is OI in its mildest form. In this setting, adults who have never sustained a fracture come to medical attention only because their family members are affected. Between these extremes is a smooth continuum of severity.
The life expectancy of subjects with nonlethal OI appears to be the same as that for the healthy population, except for those with severe OI with respiratory or neurologic complications. Although patients with lethal OI may die in the perinatal period, individuals with extremely severe OI can survive until adulthood.
Patients with OI are generally well motivated and keen to achieve as much as possible despite their physical limitations. Education is extremely important, particularly for those patients who may respond to their condition in a more negative way and therefore be prone to low self-esteem and depression.
Education of parents and families of OI patients is also important for helping them deal with the day-to-day implications and ongoing management of the disorder. For example, parents need special instructions in handling affected children. They need to know how to position the child in the crib and how to hold the child so as to minimize the risk of fractures while maintaining bonding and physical stimulation.
Living with ostogenesis imperfecta
The following tips have been developed by the Osteogenesis Imperfecta Foundation for taking care of children with OI:
Do not be afraid to touch or hold an infant with OI, but be careful; to lift the infant, spread your fingers apart and put one hand between the legs and under the buttocks, and place the other hand behind the shoulders, neck, and head
Never lift a child with OI by holding him or her under the armpits
When changing a diaper, do not pull on arms or legs or, in those with severe OI, lift the legs by the ankles
Select an infant car seat that reclines; it should be easy to place or remove your child in the seat; consider padding the seat with foam and using a layer of foam between your child and the harness
Be sure your stroller is large enough to accommodate casts; do not use a sling- or umbrella-type stroller
Follow your doctor's instructions carefully, especially with regard to cast care and mobility exercises; swimming and walking are often recommended as safe exercises
Adults with OI should avoid activities such as smoking, drinking, and taking steroids because they have a negative impact on bone density
Increasing awareness of child abuse and a lack of awareness about OI may lead to inaccurate conclusions about a family situation; always have a letter from your family doctor and a copy of your child's medical records handy
A crucial point to stress is that parents should not feel guilty if their child breaks a bone. Children must grow and develop, and fractures can occur despite all the care.
Smith R, Francis MJ, Houghton GR. The brittle bone syndrome. In: Osteogenesis Imperfecta. London: Butterworth. 1983.
Brusin JH. Osteogenesis imperfecta. Radiol Technol. 2008 Jul-Aug. 79(6):535-48. [Medline].
Cole WG. The Nicholas Andry Award-1996. The molecular pathology of osteogenesis imperfecta. Clin Orthop. 1997 Oct. 235-48. [Medline].
Cole WG. Advances in osteogenesis imperfecta. Clin Orthop. 2002 Aug. 6-16. [Medline].
Cole WG. Bone, cartilage and fibrous tissue disorders. In: Benson MKD, Fixsen JA, MacNicol MF, Parch K, eds. Children's Orthopaedics. 2002: 67-92.
Baujat G, Lebre AS, Cormier-Daire V, Le Merrer M. [Osteogenesis imperfecta, diagnosis information (clinical and genetic classification)]. Arch Pediatr. 2008 Jun. 15(5):789-91. [Medline].
Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Apr 9. 86(4):551-9. [Medline]. [Full Text].
Wallace DJ, Chau FY, Santiago-Turla C, Hauser M, Challa P, Lee PP, et al. Osteogenesis imperfecta and primary open angle glaucoma: genotypic analysis of a new phenotypic association. Mol Vis. 2014. 20:1174-81. [Medline]. [Full Text].
Sillence D. Osteogenesis imperfecta: an expanding panorama of variants. Clin Orthop. 1981 Sep. 11-25. [Medline].
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr. 16(2):101-16. [Medline].
Labuda M, Morissette J, Ward LM. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone. 2002 Jul. 31(1):19-25. [Medline].
Ward LM, Rauch F, Travers R. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002 Jul. 31(1):12-8. [Medline].
Duro Friedl EA, Ferrari Mayans L, Desalvo Portal LN, Ferrari Ruiz P, Bidondo Horno MP, Astraldi Tellechea MM. [Bruck syndrome: Osteogenesis imperfecta with congenital joint contractures.]. An Pediatr (Barc). 2008 Jul. 69(1):90-1. [Medline].
Trehan SK, Morakis E, Raggio CL, Twomey KD, Green DW. Acetabular Protrusio and Proximal Femur Fractures in Patients With Osteogenesis Imperfecta. J Pediatr Orthop. 2014 Nov 6. [Medline].
Francis MJ, Smith R, Bauze RJ. Instability of polymeric skin collagen in osteogenesis imperfecta. Br Med J. 1974 Mar 9. 1(905):421-4. [Medline].
Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000 Jun. 26(6):581-9. [Medline].
Jones D, Hosalkar H, Jones S. The orthopaedic management of osteogenesis imperfecta. Clin Orthop. 2002. 16:374-88.
Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003 Mar. 12(2):77-87. [Medline].
Forin V. [Paediatric osteogenesis imperfecta: medical and physical treatment]. Arch Pediatr. 2008 Jun. 15(5):792-3. [Medline].
Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr. 2008 Feb. 20(1):52-7. [Medline].
Sofield HA, Page MA, Mead NC. Multiple osteotomies and metal-rod fixation for osteogenesis imperfecta. J Bone Joint Surg. 1952. 34A:500-2.
Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1. 339(14):947-52. [Medline].
Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2010 Jan-Feb. 23(1-2):73-80. [Medline].
Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab. 2006 Apr. 91(4):1268-74. [Medline].
Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C. Bone Mineral Density and Fracture Rate in Response to Intravenous and Oral Bisphosphonates in Adult Osteogenesis Imperfecta. Calcif Tissue Int. 2010 Jun 11. [Medline].
Gallego L, Junquera L, Pelaz A, Costilla S. Pathological mandibular fracture after simple molar extraction in a patient with osteogenesis imperfecta treated with alendronate. Med Oral Patol Oral Cir Bucal. 2010 Jun 1. [Medline].
Castillo H, Samson-Fang L. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009 Jan. 51(1):17-29. [Medline].
Kusumi K, Ayoob R, Bowden SA, Ingraham S, Mahan JD. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age. J Bone Miner Metab. 2014 Oct 16. [Medline].
Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials. J Bone Miner Res. 2014 Nov 18. [Medline].
Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res. 2010 Apr. 51(2):123-31. [Medline]. [Full Text].
Wekre LL, Frøslie KF, Haugen L, Falch JA. A population-based study of demographical variables and ability to perform activities of daily living in adults with osteogenesis imperfecta. Disabil Rehabil. 2010. 32(7):579-87. [Medline].
|Type||Genetic||Teeth||Bone Fragility||Bone Deformity||Sclera||Spine||Skull||Prognosis|
|IA||AD*||Normal||Variable but less severe than other types||Moderate||Blue||20% scoliosis and kyphosis||Wormian bones||Fair|
|II||AD||Unknown||Very severe||Multiple fractures||Blue||NA||Wormian bones with absence of ossification||Perinatal death|
|III||AD||Dentinogenesis imperfecta||Severe||Progressive bowing of long bones and spine||Bluish at birth but white in adults||Kyphoscoliosis||Hypoplastic wormian bones||Wheelchair-bound, not ambulatory|
|IVA||AD||Normal||Moderate||Moderate||White||Kyphoscoliosis||Hypoplastic wormian bones||Fair|
|* AD = autosomal dominant; NA = not applicable.|